Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or angiotensin-converting enzyme inhibitors

Journal of the American Society of Nephrology

Volumn 18, Issue 6, 2007, Pages 1872-1879

  Feringa, Harm H H ^a   Karagiannis, Stefanos E ^a   Chonchol, Michel ^b   Vidakovic, Radosav ^a   Noordzij, Peter G ^a   Elhendy, Abdou ^c   Van Domburg, Ron T ^a   Welten, Gijs ^a   Schouten, Olaf ^a   Bax, Jeroen J ^d   Berl, Tomas ^b   Poldermans, Don ^a,e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 34249895877     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006080887     Document Type: Article

References (37)

1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B: ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease. Circulation 113: 463-654, 2006
2. Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, Wilson PW: Framingham Study. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: The Framingham Study. Arch Intern Med 163: 1939-1942, 2003
3. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D: The prevalence of peripheral arterial disease in a defined population. Circulation 71: 510-515, 1985
4. McDermott MM, Kerwin DR, Liu K, Martin GJ, O'Brien E, Kaplan H, Greenland P: Prevalence and significance of unrecognized lower extremity peripheral arterial disease in general medicine practice. J Gen Intern Med 16: 384-390, 2001
5. Selvin E, Erlinger TP: Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 110: 738-743, 2004
6. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR: Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286: 1317-1324, 2001
7. Leskinen Y, Salenius JP, Lehtimaki T, Huhtala H, Saha H: The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: Requirements for diagnostics. Am J Kidney Dis 40: 472-479, 2002
8. O'Hare AM, Glidden DV, Fox CS, Hsu CY: High prevalence of peripheral arterial disease in persons with renal insufficiency: Results from the National Health and Nutrition Examination Survey 1999-2000. Circulation 109: 320-323, 2004
9. O'Hare AM, Vittinghoff E, Hsia J, Shlipak MG: Renal insufficiency and the risk of lower extremity peripheral arterial disease: Results from the Heart and Estrogen/Progestin Replacement Study (HERS). J Am Soc Nephrol 15: 1046-1051, 2004
10. O'Hare AM, Bertenthal D, Shlipak MG, Sen S, Chren MM: Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J Am Soc Nephrol 16: 514-519, 2005
11. Jaber BL, Madias NE: Progression of chronic kidney disease: Can it be prevented or arrested? Am J Med 118: 1323-1330, 2005
12. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360: 7-22, 2002
13. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-153, 2000
14. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 295: 1556-1565, 2006
15. Hirsch AT, Duprez D: The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease. Vasc Med 8: 273-278, 2003
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999
17. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139: 137-147, 2003
18. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127: 757-763, 1997
19. O'Hare AM, Rodriguez RA, Bacchetti P: Low ankle-brachial index associated with rise in creatinine level over time: Results from the atherosclerosis risk in communities study. Arch Intern Med 165: 1481-1485, 2005
20. Chade AR, Lerman A, Lerman LO: Kidney in early atherosclerosis. Hypertension 45: 1042-1049, 2005
21. Moreno PR, Fuster V: The year in atherothrombosis. J Am Coll Cardiol 44: 2099-2110, 2004
22. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 103: 926-933, 2001
23. Song Y, Li C, Cai L: Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation. Exp Mol Pathol 76: 66-75, 2006
24. Li C, Yang CW, Park JH, Lim SW, Sun BK, Jung JY, Kim SB, Kim YS, Kim J, Bang BK: Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 286: F46-F57, 2004
25. Sandhu S, Wiebe N, Fried LF, Tonelli M: Statins for improving renal outcomes: A meta-analysis. J Am Soc Nephrol 17: 2006-2016, 2006
26. Youssef F, Gupta P, Seifalian AM, Myint F, Mikhailidis DP, Hamilton G: The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 55: 53-62, 2004
27. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B: Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90: 2056-2069, 1994
28. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H: Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability. Circulation 101: 1372-1378, 2000
29. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352: 1252-1256, 1998
30. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, Abbate M, Remuzzi G: Effect of combining ACE-inhibitor and statin in severe experimental nephropathy. Kidney Int 61: 1635-1645, 2002
31. Blanco S, Vaquero M, Gomez-Guerrero C, Lopez D, Egido J, Romero R: Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. Am J Hypertens 18: 557-565, 2005
32. Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41: 565-570, 2003
33. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, Wolfson SK: Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 88: 837-845, 1993
34. Newman AB, Sutton-Tyrrell K, Vogt MT, Kuller LH: Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA 270: 487-489, 1993
35. Lee AJ, Price JF, Russell MJ, Smith FB, van Wijk MC, Fowkes FG: Improved prediction of fatal myocardial infarction using the ankle brachial index in addition to conventional risk factors: The Edinburgh Artery Study. Circulation 110: 3075-3080, 2004
36. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D: Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326: 381-386, 1992
37. Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV: Use of ankle brachial pressure index to predict cardiovascular events and death: A cohort study. BMJ 313: 1440-1444, 1996